Online inquiry

IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4497MR)

This product GTTS-WQ4497MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD28 gene. The antibody can be applied in Lupus nephritis, Inflammatory diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001243077.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 940
UniProt ID P10747
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4497MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3212MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ6290MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ1184MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABP 501
GTTS-WQ13813MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-10987
GTTS-WQ14960MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ15033MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ8570MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ12120MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MORAb-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW